Related Experiment Video
Updated: Jun 5, 2026

Extracellular Vesicle Tissue Factor Activity Assay
Published on: December 29, 2023
Tissue factor pathway inhibitor and bacterial infection
1Blood Research Institute, Blood Center of Wisconsin, Milwaukee, WI 53201-2178, USA. susan.maroney@bcw.edu
Abstract:
See also van den Boogaard FE, Brands X, Schultz MJ, Levi M, Roelofs JJTH, van 't Veer C, van der Poll T. Recombinant human tissue factor pathway inhibitor exerts anticoagulant, anti-inflammatory and antimicrobial effects in murine pneumococcal pneumonia. This issue, pp 122-32.
Insights
Recombinant human tissue factor pathway inhibitor demonstrated anticoagulant, anti-inflammatory, and antimicrobial effects in a mouse model of pneumococcal pneumonia. This suggests potential therapeutic benefits for severe lung infections.
Area of Science:
- Pulmonary Medicine
- Hematology
- Infectious Diseases
Background:
- Pneumococcal pneumonia is a severe lung infection associated with significant morbidity and mortality.
- Tissue factor pathway inhibitor (TFPI) is a key regulator of the coagulation cascade.
- TFPI's role in infectious diseases, particularly pneumonia, is not fully understood.
Discussion:
- This study investigated the multifaceted effects of recombinant human tissue factor pathway inhibitor (TFPI) in a murine model of pneumococcal pneumonia.
- TFPI administration modulated coagulation, reduced inflammation, and exhibited antimicrobial properties.
- These findings highlight TFPI's potential as a therapeutic agent beyond its anticoagulant functions.
Key Insights:
- Recombinant human TFPI exerts significant anticoagulant effects in the context of pneumonia.
- TFPI demonstrates potent anti-inflammatory actions, mitigating key inflammatory mediators.
- Antimicrobial activity of TFPI was observed, suggesting a direct role in combating bacterial infection.
Outlook:
- Further research is warranted to explore the clinical efficacy and safety of TFPI in human pneumococcal pneumonia.
- TFPI could represent a novel therapeutic strategy for severe bacterial pneumonia, addressing both thrombosis and infection.
- Investigating the precise mechanisms of TFPI's antimicrobial and anti-inflammatory effects will be crucial for therapeutic development.
Related Concept Videos
Determinants of Bacterial Pathogenicity and Virulence
Bacterial Toxins
Defense Against Bacterial Pathogens
Phagocytes
Phagocytes are the frontline soldiers of the immune system. They include neutrophils and macrophages. Neutrophils are the most abundant type of white blood cell and are quickly mobilized to the site of infection. Macrophages are larger cells that patrol...
Gene Regulation in Microbial Communities: Quorum Sensing
Antimicrobial Proteins
Interferons
Interferons (IFNs) are proteins produced by lymphocytes, macrophages, and fibroblasts infected with viruses. While IFNs cannot prevent viruses from entering and...
Regulation of Bacterial Virulence

